Literature DB >> 33296794

Depletion of glioma stem cells by synergistic inhibition of mTOR and c-Myc with a biological camouflaged cascade brain-targeting nanosystem.

Yuying Ma1, Jinnan Zhang2, Yalan Rui1, Janiqua Rolle1, Tian Xu1, Zhiyu Qian3, Yueqing Gu4, Siwen Li5.   

Abstract

Glioma stem cells (GSCs), as a subpopulation of stem cell-like cells, have been proposed to play a crucial role in the progression of drug-resistance in glioblastoma (GBM). Therefore, the targeted eradication of GSCs can serve as a promising therapeutic strategy for the reversal of drug-resistance in GBM. Herein, the effects of silencing c-Myc and m-TOR on primary GBM cells extracted from patients were investigated. Results confirmed that dual inhibition treatment significantly (p < 0.05) and synergistically suppressed GSCs, and consequently reversed TMZ-resistance when compared with the single treatment group. Subsequently, to facilitate effective crossing of the BBB, a biological camouflaged cascade brain-targeting nanosystem (PMRT) was created. The PMRT significantly inhibited tumor growth and extended the lifespan of orthotopic transplantation TMZ-resistant GBM-grafted mice. Our data demonstrated that PMRT could precisely facilitate drug release at the tumor site across the BBB. Simultaneously, c-Myc and m-TOR could serve as synergistic targets to eradicate the GSCs and reverse GBM resistance to TMZ.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biological camouflaged nanosystem; Cascade brain-targeting; Glioma stem cells; Inhibition of mTOR and c-Myc; Synergistic therapy

Year:  2020        PMID: 33296794     DOI: 10.1016/j.biomaterials.2020.120564

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  1 in total

1.  Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM.

Authors:  Bao Liu; Qifeng Ji; Ying Cheng; Miao Liu; Bangle Zhang; Qibing Mei; Daozhou Liu; Siyuan Zhou
Journal:  J Nanobiotechnology       Date:  2022-03-27       Impact factor: 10.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.